Gain Therapeutics Announces R&D Day and Participation in Upcoming Conferences | 2022-01-18 | Press Releases

0

– Neuroscience and Beyond: Harnessing Computer Technology and Allosteric Modulators to Drug the Indugable –

– 18and Annual WORLD Symposium –

– AD/PD™ 2022 –

BETHESDA, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that n have ever been targeted in neurodegenerative diseases and lysosomal storage disorders, announced today that it will host an R&D Day and attend upcoming scientific conferences. Please see additional details below:

Details of the R&D day event and conferences:

Event: Neuroscience and Beyond: Harnessing Computer Technology and Allosteric Modulators to Drug the Indestructible
Website: Registration link
Dated: February 4, 2022
Time: 10:00 a.m. ET
Conference: 18and Annual WORLD Symposium
Website: https://worldsymposia.org
Dated: February 7 – 11, 2022
Conference: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Website: https://adpd.kenes.com
Dated: March 15 – 20, 2022

Additional details on registration, speakers and agendas will follow and will be posted in the Events section of the Gain website.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. positions itself at the intersection of technology and healthcare and is focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never been targeted before, Gain opens up new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was created in 2017 with the support of its founders and institutional investors. It has received financial support from the Michael J. Fox Foundation for Parkinson’s Disease Research (MJFF) and the Silverstein Foundation for Parkinson’s Research with GBA, as well as the Eurostars-2 joint program with a European Union co-funding. Research Horizon 2020 and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss company, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

For more information visit https://www.gaintherapeutics.com/

Investor and media contacts:

Gain Therapeutics Investor Contact:

Daniel Ferry

LifeSci Advisors

+1 (617) 430-7576

[email protected]

Media contact for Gain Therapeutics:

Joleen Schultz

Joleen Schultz & Associates

+1 760-271-8150

[email protected]

main logo


Source link

Share.

Comments are closed.